BT-001

BT-001 is a genetically engineered oncolytic virus based on a modified vaccinia virus (Copenhagen strain, double deleted). It is designed for cancer immunotherapy and armed with two key payloads: a human recombinant anti-CTLA-4 monoclonal antibody (mAb, clone 4-E03 IgG1) and the cytokine GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor). It acts by selectively infecting and replicating within tumor cells, leading to direct lysis and the local expression of anti-CTLA-4 and GM-CSF. The anti-CTLA-4 mAb blocks CTLA-4 signaling, depleting Tregs and promoting effector T cell activity against tumors. GM-CSF recruits dendritic cells and other immune effectors to enhance antigen presentation.

Other names

Oncolytic vaccinia virus expressing anti-CTLA-4 and GM-CSFModified vaccinia virus (Copenhagen strain, double deleted)MVV-CTLA4-GMCSF

BT-001 is an oncolytic virus that selectively infects and replicates within tumor cells, leading to tumor lysis. It also expresses a human anti-CTLA-4 antibody to block CTLA-4 signaling, depleting Tregs and promoting T cell activity. Furthermore, it produces GM-CSF to enhance immune cell recruitment and activation within the tumor microenvironment.